Ebola virus
Generated by GPT-5-miniExpansion Funnel Raw 33 → Dedup 0 → NER 0 → Enqueued 0
| Ebola virus | |
|---|---|
 | |
| Name | Ebola virus |
| Genome | Negative-sense single-stranded RNA |
| Family | Filoviridae |
| Genus | Zaire ebolavirus (representative) |
| Diseases | Ebola virus disease |
| First isolated | 1976 |
| Hosts | Humans, nonhuman primates, bats (suspected) |
Ebola virus Ebola virus is a member of the family Filoviridae that causes severe hemorrhagic fever in humans and nonhuman primates. First identified during simultaneous outbreaks in 1976, it is characterized by filamentous virions, high case-fatality ratios in many outbreaks, and episodic emergence linked to ecological and sociopolitical factors. Research on Ebola virus spans virology, clinical medicine, public health, and conservation, and involves institutions such as the World Health Organization, Centers for Disease Control and Prevention, and multiple national public health agencies.
Virology and Structure
Ebola virus is an enveloped, filamentous virus with a negative-sense, single-stranded RNA genome encoding seven structural proteins and several nonstructural factors. Structural components include the surface glycoprotein (GP), matrix proteins VP40 and VP24, nucleoprotein (NP), and polymerase L, which together mediate attachment, entry, assembly, and replication. The three-dimensional morphology of virions and the architecture of ribonucleoprotein complexes have been elucidated using cryo-electron microscopy and X-ray crystallography by teams from institutions such as the National Institutes of Health and research groups at universities including Harvard University and Johns Hopkins University. Genetic variation among species and strains, studied through phylogenetic analysis by groups like the Broad Institute and Wellcome Sanger Institute, informs classification within Filoviridae and underpins molecular diagnostics.
Transmission and Epidemiology
Human outbreaks of Ebola virus disease typically begin with zoonotic spillover from a reservoir species, with fruit bats implicated by ecological and molecular studies performed by researchers at centers such as the Institut Pasteur and the University of Oxford. Subsequent human-to-human spread occurs via direct contact with infected bodily fluids, contaminated materials, and during unsafe clinical or mortuary practices; nosocomial transmission has been documented in settings associated with Médecins Sans Frontières deployments and regional hospitals. Epidemiological investigation and modeling by teams at Imperial College London and the London School of Hygiene & Tropical Medicine have characterized transmission dynamics, reproduction numbers, and the impact of interventions like isolation and safe burial practices. International travel and porous borders involving countries such as Guinea, Liberia, and Sierra Leone have influenced the geographic spread during major epidemics.
Clinical Presentation and Pathogenesis
Ebola virus disease typically begins with an abrupt onset of fever, myalgia, and fatigue, progressing in severe cases to vomiting, diarrhea, hemorrhage, multiorgan dysfunction, and shock. Pathogenesis involves viral replication in monocytes, macrophages, and dendritic cells, dysregulated immune responses, endotheliopathy, and coagulopathy; molecular mechanisms have been explored in studies at institutions such as University of Texas Medical Branch and Rockefeller University. Host factors including age, comorbidities, and genetic background influence severity; clinical cohorts from outbreaks analyzed by Harvard Medical School and the University of North Carolina have informed prognostic models. Pregnancy and pediatric cases present distinct risks and management challenges noted in field reports from organizations like Save the Children and UNICEF.
Diagnosis and Laboratory Methods
Laboratory confirmation of Ebola virus infection relies on molecular assays, antigen detection, and serology. Reverse transcription–polymerase chain reaction (RT-PCR) targeting viral gene sequences is the gold standard used in diagnostic laboratories including those at the Centers for Disease Control and Prevention and national reference labs. Rapid diagnostic tests developed by public–private partnerships and manufacturers have been deployed in outbreak settings coordinated by World Health Organization teams. Virus isolation in high-containment laboratories (biosafety level 4) at facilities such as the National Microbiology Laboratory (Canada) enables research but is not required for routine diagnosis. Field-adapted sampling, cold-chain logistics, and laboratory networking coordinated by entities like the African Union and regional public health institutes underpin timely case detection.
Treatment and Prevention
Supportive care—fluid resuscitation, electrolyte correction, hemodynamic support, and management of co-infections—remains the cornerstone of clinical management, with specialized care provided in treatment centers run by organizations such as Médecins Sans Frontières and national Ministries of Health. Antiviral therapeutics, including monoclonal antibody regimens evaluated in randomized controlled trials supported by the National Institutes of Health and pharmaceutical partners, have demonstrated improved survival. Vaccination strategies using recombinant vesicular stomatitis virus–based vaccines have been implemented during outbreaks under guidance from World Health Organization emergency responses and regulatory bodies like the European Medicines Agency. Infection prevention and control measures, contact tracing, safe burial teams, and community engagement led by local authorities and international NGOs are critical to outbreak control.
History and Notable Outbreaks
Ebola virus was first recognized in simultaneous 1976 outbreaks near Yambuku in what was then Zaire and in Nzara in Sudan, prompting early investigations by teams linked to the Institut Pasteur and the Centers for Disease Control and Prevention. Notable subsequent events include the 1995 Kikwit outbreak in Democratic Republic of the Congo and the large 2013–2016 epidemic centered in West Africa affecting Guinea, Liberia, and Sierra Leone, which mobilized international responses from organizations including World Health Organization and United Nations agencies. More recent outbreaks in Democratic Republic of the Congo involved complex interactions with regional conflict, humanitarian agencies such as International Committee of the Red Cross, and targeted vaccination campaigns. Scientific, public health, and policy responses to major outbreaks have influenced global health security frameworks advocated by institutions like the Global Health Security Agenda and the Bill & Melinda Gates Foundation.